Neurogene Inc NGN-401 Phase 1/2 Clinical Data Update Transcript
Good morning, and welcome to Neurogene's Webcast and Conference Call. Please be advised that this event is being recorded. I will now turn the call over to Lina Li, Executive Director of Investor Relations at Neurogene. Please proceed.
Thank you. Good morning, everyone, and thank you for joining us today to review the Phase II data of NGN-401 for the treatment of Rett syndrome. Before we get started, I'd like to remind everyone that we will be making forward-looking statements today. These statements involve known and unknown risks and uncertainties, which may cause our actual results to differ materially from those presented today. I encourage you to review our latest SEC filings, including our Form 10-K and most recent Form 10-Q, for a complete discussion of these risk factors. All of the information we will be presenting is as of today's. Unless noted otherwise, and we undertake no obligation to update any forward-looking statements. Our speakers from NeuroGene today are Dr. Rachel McMinn,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
